Format

Send to

Choose Destination

See 1 citation in Int J Cardiol 2015:

Int J Cardiol. 2015 Aug 1;192:33-9. doi: 10.1016/j.ijcard.2015.05.040. Epub 2015 May 9.

Predictive value of galectin-3 for incident cardiovascular disease and heart failure in the population-based FINRISK 1997 cohort.

Author information

1
Department of General and Interventional Cardiology, Hamburg University Heart Centre, Hamburg, Germany; Deutsches Zentrum für Herzkreislaufforschung (DZHK e.V.); Partner site Hamburg, Lübeck, Kiel, Germany.
2
National Institute for Health and Welfare, Department of Chronic Disease Prevention, Helsinki, Finland.
3
Department of General and Interventional Cardiology, Hamburg University Heart Centre, Hamburg, Germany.
4
Department of General and Interventional Cardiology, Hamburg University Heart Centre, Hamburg, Germany; Deutsches Zentrum für Herzkreislaufforschung (DZHK e.V.); Partner site Hamburg, Lübeck, Kiel, Germany; Centre of Excellence for Public Health Northern Ireland, Queens University Belfast, Northern Ireland, UK; MRC Epidemiology Unit, University of Cambridge, UK.
5
National Institute for Health and Welfare, Department of Chronic Disease Prevention, Helsinki, Finland. Electronic address: veikko.salomaa@thl.fi.

Abstract

OBJECTIVES:

Galectin-3 is an emerging biomarker playing an important, complex role in intracellular pathways of cardiovascular diseases and heart failure. We aimed therefore to investigate the predictive value of galectin-3 for incident cardiovascular disease and heart failure.

METHODS:

Galectin-3 levels were measured in 8444 participants of the general population-based FINRISK 1997 cohort. Cox proportional hazards regression analyses, adjusting for traditional Framingham risk factors, prevalent valvular heart disease, eGFR (estimated glomerular filtration rate) as well as NT-proBNP, were used to examine the predictive power of galectin-3. Measurements of discrimination and reclassification using 10-fold cross-validation were performed to control for over-optimism. Cardiovascular death (CD), all-cause mortality, myocardial infarction (MI), ischemic stroke (hemorrhagic strokes were excluded) and heart failure (HF) were used as endpoints.

RESULTS:

During the follow-up of up to 15 years there were in total 1136 deaths from any cause, 383 cardiac deaths, 359 myocardial infarctions, 401 ischemic strokes and 641 cases of incident heart failure. Hazard ratios (HR) were statistically significant for all-cause mortality (1.12, p < 0.001), cardiac death (1.15, p = 0.033) and heart failure (1.10, p = 0.049). Statistical significance was lost when analyzing by gender except for all-cause mortality. No significant improvements were observed in model discrimination or overall reclassification upon inclusion of galectin-3. Compared to NT-proBNP, the predictive power of galectin-3 was weaker but both remained significant, independently of each other.

CONCLUSION:

Galectin-3 levels were predictive for future cardiovascular events but improvements in discrimination and reclassifications were modest.

KEYWORDS:

Biomarker; Cardiovascular disease; Galectin; Heart failure

PMID:
25985013
DOI:
10.1016/j.ijcard.2015.05.040
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center